Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bas W G van Rhijn

Showing results (31-40 of 215) with videos related to

Pageof 22
Sort By:
European Urology|March 18, 2015
Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014Floris H Groenendijk, Elisabeth E Fransen van de Putte, Bas W G van Rhijn, et al.
The Journal of Urology|December 31, 2013
Penile sparing surgery for penile cancer-does it affect survival?Rosa S Djajadiningrat, Erik van Werkhoven, Wim Meinhardt, et al.
European Urology Open Science|February 16, 2023
Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management StrategiesLaura S Mertens, Vidit Sharma, Surena F Matin, et al.
The Journal of Urology|August 21, 2012
Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?Laura S Mertens, Richard P Meijer, J Martijn Kerst, et al.
The American Journal of Surgical Pathology|May 29, 2023
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System PerformanceMichelle R Downes, Arndt Hartmann, Steven Shen, et al.
Current Opinion in Urology|July 1, 2015
Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladderElisabeth E Fransen van de Putte, Mark A Behrendt, Garry L S Pigot, et al.
European Urology|July 7, 2009
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategyBas W G van Rhijn, Maximilian Burger, Yair Lotan, et al.
Clinical Genitourinary Cancer|April 16, 2021
The Diagnostic Value of FDG-PET/CT for Urachal CancerLaura E Stokkel, Marcel P M Stokkel, Maarten L Donswijk, et al.
Urologia Internationalis|February 8, 2022
Robot-Assisted Partial Cystectomy versus Open Partial Cystectomy for Patients with Urachal CancerLaura E Stokkel, Maaike W van de Kamp, Eva E Schaake, et al.
The Journal of Urology|November 17, 2009
Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trialMadelon N M van der Aa, Ewout W Steyerberg, Chris Bangma, et al.
Pageof 22

Showing results (31-40 of 215) with videos related to

Sort By:
Pageof 22
European Urology|March 18, 2015
Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014Floris H Groenendijk, Elisabeth E Fransen van de Putte, Bas W G van Rhijn, et al.
The Journal of Urology|December 31, 2013
Penile sparing surgery for penile cancer-does it affect survival?Rosa S Djajadiningrat, Erik van Werkhoven, Wim Meinhardt, et al.
European Urology Open Science|February 16, 2023
Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management StrategiesLaura S Mertens, Vidit Sharma, Surena F Matin, et al.
The Journal of Urology|August 21, 2012
Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?Laura S Mertens, Richard P Meijer, J Martijn Kerst, et al.
The American Journal of Surgical Pathology|May 29, 2023
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System PerformanceMichelle R Downes, Arndt Hartmann, Steven Shen, et al.
Current Opinion in Urology|July 1, 2015
Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladderElisabeth E Fransen van de Putte, Mark A Behrendt, Garry L S Pigot, et al.
European Urology|July 7, 2009
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategyBas W G van Rhijn, Maximilian Burger, Yair Lotan, et al.
Clinical Genitourinary Cancer|April 16, 2021
The Diagnostic Value of FDG-PET/CT for Urachal CancerLaura E Stokkel, Marcel P M Stokkel, Maarten L Donswijk, et al.
Urologia Internationalis|February 8, 2022
Robot-Assisted Partial Cystectomy versus Open Partial Cystectomy for Patients with Urachal CancerLaura E Stokkel, Maaike W van de Kamp, Eva E Schaake, et al.
The Journal of Urology|November 17, 2009
Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trialMadelon N M van der Aa, Ewout W Steyerberg, Chris Bangma, et al.
Pageof 22